Novartis move damages CAR-T confidenceSwiss pharma axes gene therapy unit, causing investor angst. Share XNovartis move damages CAR-T confidencehttps://pharmaphorum.com/news/novartis-damages-confidence-car-t/
Novartis on track to bring first CAR-T to marketNovartis says its chimeric antigen receptors (CAR-T) candidate is on track for filing in 2017, which could make Share XNovartis on track to bring first CAR-T to markethttps://pharmaphorum.com/news/novartis-on-track-to-be-first-car-t-to-market/
After taking lead in CAR-T, Cellectis drug snapped up by Pfizer and ServierPfizer and Servier have snapped up the rights to UCART19, after the immunotherapy treatment showed hugely encouraging results Share XAfter taking lead in CAR-T, Cellectis drug snapped up by Pfizer and Servierhttps://pharmaphorum.com/news/after-taking-lead-in-car-t-cellectis-drug-snapped-up-by-pfizer-and-servier/